{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-049754","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.299269+00:00","generated_at":"2026-05-15T01:09:56.923892+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Cadrenal completes FDA End-of-Phase 2 meeting; gets guidance for Phase 3 pivotal trial of CAD-1005 in HIT","bullets":["Phase 2 data showed >25% absolute reduction in thrombotic events when CAD-1005 added to standard anticoagulant therapy.","Planned Phase 3 trial: randomized, blinded, placebo-controlled; ~120 patients at up to 50 sites worldwide.","Primary endpoint: incidence of new or worsening thrombotic events (centrally adjudicated) in SRA-confirmed HIT patients.","Projected NDA submission in 2029; first randomized, blinded, placebo-controlled registration trial in HIT."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-049754","json":"https://secwatch.observer/filing/0001213900-26-049754.json","markdown":"https://secwatch.observer/filing/0001213900-26-049754.md","text":"https://secwatch.observer/filing/0001213900-26-049754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026049754/0001213900-26-049754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026049754/ea0288376-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:09:56.923892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}